Completed PHASE3 INTERVENTIONAL 4-arm NCT02414854

Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest)

A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma

Sponsor: Regeneron Pharmaceuticals

Conditions Asthma

Interventions Albuterol/Salbutamol Dupilumab Inhaled corticosteroid (ICS) therapy Levalbuterol/Levosalbutamol Placebo

Updated 12 times since 2017 Last updated: Oct 19, 2018 Started: Apr 27, 2015 Primary completion: Jul 29, 2017 Completion: Nov 23, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Asthma, this trial is completed. The trial is conducted by Regeneron Pharmaceuticals and has accumulated 12 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

12 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Nov 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 7 earlier versions

Jul 2018 — Nov 2018 [monthly]

Completed PHASE3
Jun 2018 — Jul 2018 [monthly]

Completed PHASE3
Dec 2017 — Jun 2018 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
Oct 2017 — Dec 2017 [monthly]

Active Not Recruiting PHASE3
Jul 2017 — Oct 2017 [monthly]

Active Not Recruiting PHASE3
Feb 2017 — Jul 2017 [monthly]

Active Not Recruiting PHASE3
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE3

First recorded

Apr 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Regeneron Pharmaceuticals
Sanofi

Data source: Sanofi

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akashi-Shi, Japan , Amarillo, United States , Ancona, Italy , Ankara, Turkey (Türkiye) , Asahikawa-Shi, Japan , Austin, United States , Aventura, United States , Bahía Blanca, Argentina , Bakersfield, United States , Baltimore, United States and 289 more locations